Trial site
JSC K. Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, 0159, GeorgiaNot linked to an institution yet
- 11running trials
- 2closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 23 trials
- Phase 11 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Completed2 trials
- Recruiting2 trials
- Not yet recruiting1 trial
- Lead sponsor
- Regeneron Pharmaceuticals3 trials
- Amgen2 trials
- DiaMedica Therapeutics Inc1 trial
- Gilead Sciences1 trial
- H. Lundbeck A/S1 trial
- and 5 more
Running trials
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· Phase 1· Shanghai Henlius Biotech· Source
Contact: Yinping Zhong
Active, not recruiting
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297· Phase 3· X4 Pharmaceuticals· Source
Contact: Patient Affairs and Advocacy
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source
Contact: John Mei
Active, not recruiting
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555· Phase 3· Amgen· Source
Active, not recruiting
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source
Active, not recruiting
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931· Phase 2· Gilead Sciences· Source
Active, not recruiting
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source
Contact: Shanique Smythe - Peterkin
Active, not recruiting
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· Phase 4· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error